Table 2 Demographics and clinical characteristics of participants with PsA and healthy participants

AGE (years)

53.9 ± 8.9

54.23 ± 9.3

BMI (kg/m²⁾

29.3 ± 4.5)

24.4 ± 3.4*

SEX (M: F)

5: 16

5: 16

DISEASE DURATION (years)

11.5 ± 10.2 (Median = 6, IQR: 12)

–

 Normal

16 (94%)

 High

1 (6%)

 DMARDs

6 (30%)

 Biological therapy

5 (25%)

 DMARDs and Biological therapy

7 (35%)

Foot pain (0 to 10 points)

5.6 ± 1.9

0.2 ± 0.6*

Knee pain (0 to 10 points)

4.7 ± 2.6

0.5 ± 1.2*

Hip pain (0 to 10 points)

4.8 ± 2.9

0.1 ± 0.3*

Lower back pain (0 to 10 points)

5.4 ± 2.7

1.6 ± 2.5*

 FFI-Pain (%)

55.7 ± 18.3

–

 FFI-Disability (%)

44.6 ± 22.7

 FFI-Activity limitation (%)

34.3 ± 24.4

 FFI-Total (%)

47.02 ± 18.3

Pain sites

–

 Toes

15 (71%)

 Metatarsals

16 (76%)

 Heels

11 (52%)

 Ankles

17 (81%)

Deformities

–

 Rearfoot valgus

13 (62%)

 Hallux valgus

5 (24%)

 Hallux rigidus

4 (19%)

 Hammer/claw toes

14 (67%)